KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), today hosted an Analyst and Investor Day in New York City that focused on the Company’s clinical programs, including its most advanced assets, TRV130 and TRV027. The meeting featured presentations from members of the Trevena management team and leading experts in acute heart failure and pain management, including:
Help employers find you! Check out all the jobs and post your resume.
